By Connor Hart

Worthington Enterprises posted a higher profit that came in ahead of analyst estimates in its fiscal second quarter, boosted by a recent acquisition and higher margins. The building- and consumer-products company said its profit grew to $28.3 million in the recent quarter, up from $24.3 million a year earlier. Adjusted per-share earnings of 60 cents beat the 52 cents forecast by analysts, according to FactSet. Lower expenses in its consumer-products business resulted in higher gross margins, it said. Shares jump 14%, to $43.59, in after-hours trading.

Corvus Pharmaceuticals said it would announce interim data from a Phase 1 clinical trial of its treatment for moderate to severe eczema. The clinical-stage biopharmaceutical company said it will announce its data on Wednesday in a press release and present during a conference call and webcast. Its treatment, soquelitinib, is an investigational treatment that selectively inhibits ITK, an enzyme that is expressed mostly in T cells and plays a role in T cell and natural killer cell immune function. Shares soar 16%, to $8.60, in postmarket trading.

CommScope Holding closed a comprehensive refinancing that will enable it to address upcoming debt maturities. The provider of infrastructure solutions for communications networks entered new agreements with a group of existing lenders, including a $3.15 billion term loan and $1 billion in notes, maturing in 2029 and 2031, respectively. Proceeds from these agreements will enable the company to fully repay its senior unsecured notes due 2025, as well as its existing senior secured term loan facility, it said. Shares climb 12%, to $6.28, in after-hours trading.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

December 17, 2024 18:18 ET (23:18 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.